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The survival rate of cardiac arrest patients is less than 10%; therefore, development of 
a therapeutic strategy that improves their prognosis is necessary. Herein, we searched 
data collected from medical facilities throughout Japan for drugs that improve the survival 
rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of 
cardiac arrest patients, were extracted using “TargetMine,” a drug discovery tool. We 
investigated whether the candidate drugs were among the drugs administered within 
1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan 
Medical Data Center. Logistic regression analysis was performed, with the explanatory 
variables being the presence or absence of the administration of those candidate drugs 
that were administered to ≥10 patients and the objective variable being the “survival 
discharge.” Adjusted odds ratios for survival discharge were calculated using propensity 
scores for drugs that significantly improved the proportion of survival discharge; the 
influence of covariates, such as patient background, medical history, and treatment 
factors, was excluded by the inverse probability-of-treatment weighted method. Using 
the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. 
Drugs not approved in Japan, oral medicines, and external medicines were excluded. 
Then, we investigated whether the candidate drugs were administered to the 2,227 
cardiac arrest patients included in this study. The results of the logistic regression analysis 
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INTRODUCTION
Despite advances in treatment, cardiac arrest still results in 
a high mortality rate. In the United States alone, more than 
550,000 cardiac arrest cases are reported annually, with the 
survival discharge rate being only 12% and 24.8% for out-of-
hospital and in-hospital patients, respectively (The American 
Heart Association, 2013). Considering the increase in aging 
population, the number of cardiac arrest patients is also expected 
to increase; hence, there is an urgent need to develop a treatment 
that improves the prognosis of patients suffering cardiac arrest.
Cardiac arrest damages heart functions and those of other 
organs. Particularly, it results in myocardial dysfunction at the 
early stages after resuscitation; moreover, circulation becomes 
very unstable (Jentzer et al., 2015). Myocardial dysfunction 
is associated with early death, and if improvement in cardiac 
function cannot be achieved within 24 h, conditions such as 
multiple organ failure, which have poor prognosis, are known 
to occur (Laurent et al., 2002). Therefore, normalization of 
hemodynamics is very important for improving the prognosis 
after cardiac arrest.
In recent years, drug repositioning (DR) has attracted 
attention as a strategy of drug development. In the DR approach, 
new pharmacological effects of already approved drugs with 
known safety for humans are identified. These drugs are then 
used as new therapeutic agents for other diseases according to the 
identified effect (Ashburn and Thor, 2004; Zamami et al., 2017). 
The number of new drugs introduced in the market is decreasing 
yearly because the development of new drugs is expensive and 
time-consuming (Reuters, 2011). The main advantage of using 
the DR approach is that it can reduce drug development time 
and cost. Moreover, it reduces the risk of development failure due 
to unintended adverse effects and pharmacokinetic problems 
in the clinical trial stage. Various types of big data are now 
available, and utilization of these data can be highly useful for 
the DR approach. We anticipate that DR can contribute to the 
development of therapeutic agents that improve prognosis of 
cardiac arrest patients.
One such big data in the field of life science is the drug discovery 
science database. It includes a wide variety of information such 
as chemical structures, physical properties, pharmacological 
actions, and genes related to diseases. TargetMine has been 
developed by the National Institutes of Biomedical Innovation, 
Health and Nutrition (Japan). It integrates more than 30 databases 
on bioinformatics worldwide (Chen et al., 2016). It can be used 
to identify related diseases and drugs based on a specific gene. 
Similarly, a representative medical information big data for the 
medical sciences is Japan Medical Data Center (JMDC) Claims 
Database. It is a database of 5.6 million cases collected from 
Japan’s health insurance association, which includes information 
on the diagnosis of diseases and prescription medicines and 
reflects the actual clinical practices. Using these databases, it is 
possible to evaluate the efficacy and safety of drugs in the real-
world setting (Sugiyama et al., 2016; Yokoyama et al., 2018).
It is difficult to develop an experimental drug for cardiac 
arrest due to the urgency of treatment and ethical problems. 
However, we can use the DR approach by utilizing drug discovery 
science databases and medical information databases to identify 
candidate drugs expected to be effective in humans. Therefore, 
in this study, we aimed to search for drugs that can improve the 
survival rate of cardiac arrest patients using drug discovery tools 
and large-scale medical databases through the DR approach.
METHODS
Extraction of Candidate Drugs by 
Targetmine
TargetMine internally integrates and combines various data from 
around the world. It is possible to use it for drug development 
by simultaneously specifying conditions such as target genes, 
proteins, and pharmacological actions, and thus simplifying 
complicated tasks. Compared with other data warehousing tools, 
TargetMine has simpler operation, and users can collect and 
prioritize information quickly and efficiently without the need for 
special programming skills (Chen et al., 2011; Chen et al., 2016). 
The occurrence of cardiac arrest causes systemic circulatory 
failure and hypoxia. Therefore, we focused our literature search 
on vasodilators because of their use in maintaining circulation 
after resumption of heart functioning (Yuuki et al., 1991). In this 
study, we used Anatomical Therapeutic Chemical Classification 
System (ATC) codes (widely used as a method to classify 
medicines according to efficacy, site of action, target organ, and 
chemical characteristics) as an extraction method of candidate 
drugs. We searched for pharmaceutical ingredients with an ATC 
code associated with vasodilator effect (Supplementary Table 
1). TargetMine is a comprehensive tool and is suitable for this 
study because it can be used to extract information on drugs 
showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that 
were administered to ≥10 patients showed significant association with improvement in 
the proportion of survival discharge. Further analyses using propensity scores revealed 
that the adjusted odds ratios for survival discharge for patients administered isosorbide 
dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it 
can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel 
therapeutic agents for improving the prognosis of cardiac arrest patients.
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with pharmacological actions that correspond to specific ATC 
classifications.
Analysis of Large-Scale Medical 
Information
The claims database used in analysis was provided by the Japan 
Medical Data Center (JMDC), which includes approximately 
3 million cases (as of November 2015) of receipt information. 
Information from medical hospital receipts, Diagnosis 
Procedure Combination (DPC) receipts, medical out-of-
hospital receipts, and dispensing receipts was integrated. It 
was possible to obtain information, including disease name, 
medical treatment, and the dispensed items, from the insurance 
documents (Supplementary Table 2–8). Moreover, since 
a unique ID is given to each participant, if one patient visits 
multiple medical institutions, it is possible to trace a series of 
processes from the occurrence of a disease to its convergence. 
Nevertheless, since all data are highly encrypted unlinkable 
anonymized information, it is not possible to identify an 
individual. The receipt dataset used in this study is provided 
in seven files: “patient information,” “receipt information,” 
“facility information,” “doctor information,” “injury 
information,” “pharmaceutical information,” and “medical 
treatment information.” The items contained in each file and 
their contents are shown in Supplementary Tables 2, 3, 4, 5, 
6, 7, and 8. It should be noted that the diagnostic names in this 
dataset are used by the WHO for referring to causes of death 
and disease. The classification was based on the 10th edition of 
“International Statistical Classification of Diseases and Related 
Health Problems” (ICD-10). Drugs were classified according 
to the Anatomical Therapeutic Chemical Classification System 
(ATC classification) developed by the European Pharmaceutical 
Market Research Association (EphMRA). From January 2005 
to May 2014, patients with the following (ICD-10) codes 
were classified as cardiac arrest patients (n = 2,546): I469 for 
cardiac arrest, I472 for pulseless ventricular tachycardia, I490 
for transient ventricular fibrillation; and Japan specific medical 
action codes: J046 for non-thoracotomy heart massage, J047 
for counter shock. Among these patients, those with traumatic 
cardiac arrest or <18 years of age or unconfirmed diagnosis or 
having missing data were excluded. Finally, 2,227 patients were 
included in the study. Cardiac arrest date was defined as the 
date at which the diagnosis of cardiac arrest was started; if the 
diagnosis date was unknown, the date on which the practice 
for cardiac arrest was performed was used. If multiple cardiac 
arrests occurred during the study period, the first date was 
taken as the patient’s cardiac arrest date. We used the presence 
or absence of “the fee for providing treatment information at 
discharge” in claim data to define survival discharge. Patients 
who were charged this fee within 1 year from the day of cardiac 
arrest were defined as survival discharge patients. The data were 
processed using Microsoft Access 2013, and the information 
contained in the seven files described above was linked based 
on the patient ID. Because data about “birth date,” “join date,” 
“JMDC data start date,” and “medical treatment date” could 
not be obtained, these dates were all set to the first day of that 
month. In addition, “the withdrawal date” and “JMDC data 
end date” were set to the last day of that month. In case the 
“medical care start date,” the “prescription date of medicine,” 
or the “treatment date” were blank, the “consultation date” was 
used instead.
Narrowing Down Candidate Drugs
First, the drugs that were not currently approved in Japan were 
excluded. Parenteral administration suitable for the the patients 
with cardiac arrest because of they suffer from sever condition and 
are unconscious. Therefore, the drugs for which no injectable form 
was available were excluded. Subsequently, information of drugs 
administered within 1 month after cardiac arrest was extracted from 
2,227 cardiac arrest cases identified as target patients. Of these, drugs 
administered in ≤10 patients were excluded as statistically reliable 
results could not be obtained when the number of patients was very 
small. The correlation between the administration of the candidate 
drugs and the survival discharge within 1 year was analyzed by 
logistic regression analysis. The administration of each candidate 
drug (diltiazem, disopyramide, flecainide, verapamil, isosorbide 
nitrate, nicardipine, and nitroglycerin) within 1 month from the 
cardiac arrest date was set as the explanatory variable, and the 
survival discharge within 1 year from the cardiac arrest date was set 
as the objective variable (Figure 1). The adjusted odds ratios (ORs) 
were calculated for the drugs showing a significant relationship with 
survival discharge in simple logistic regression analysis. The covariates 
used for the adjustment are shown  n Supplementary Table 9.
Statistical Analysis
Continuous variables are presented as the mean ± standard 
deviation (SD) and categorical variables by using frequencies and 
percentages. To compare the effects of administration of each drug 
on survival discharge, simple logistic regression was performed 
with administration of diltiazem, disopyramide, flecainide, 
verapamil, isosorbide dinitrate, nicardipine, and nitroglycerin 
as covariates (Table 3). Isosorbide dinitrate, nitroglycerin, and 
nicardipine were divided into two groups based on the presence 
or absence of administration. Standardized mean differences 
(Tables 4, 5, 6) were calculated after adjusting each covariate 
using the inverse probability of treatment weighting (IPTW) 
method, and the variation of the covariates in both groups 
was examined. Using the IPTW method, adjusted ORs were 
calculated for comparing the rates of survival discharge between 
the two groups (Table 7). Analyses were performed using R 
statistical software version 3.1.2., and statistical significance was 
defined as a p  < 0.05.
Ethics Statement
This study was carried out in accordance with the recommendations 
of the Ethical Guidelines for Epidemiological Research by the 
Ministry of Health, Labour and Welfare. The protocol was approved 
by the ethics committees of Okayama University Graduate School 
of Medicine, Dentistry and Pharmaceutical Sciences and Okayama 
University Hospital (no. 105056). One cannot identify individuals 
from JMDC’s claims database because all personal data including 
names are deleted and converted to an ID that cannot be linked with 
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any personal information. Since this study was an observational 
study with anonymized information, no treatment intervention, 
and no collection of human samples, the requirement of obtaining 
informed consent was waived by the ethics committee.
RESULTS
Candidate Drug Data Extraction Using 
Targetmine
Of the drugs shortlisted using TargetMine, drugs with ATC 
code “C01B” included 51 drugs, “C01DA,” “C02CA,” and 
“C02CC” included 10 drugs each, “C04” included 52 drugs, and 
“C08” included 44 drugs. The total number of drugs excluding 
duplicates was 165 (Table 1).
Of these 165 candidate drugs, 39 were excluded, including 
those not either approved in Japan or those for which no 
injectable form was available. After further shortlisting for the 
drugs administered within 1 month from the day of cardiac 
arrest, 11 drugs were obtained. Finally, after exclusion of drugs 
that were used by ≤10 patients and those included in statistical 
analysis as covariates, seven drugs were shortlisted as the drug 
candidates for this study. The names and frequencies of drug 
administration of each drug are shown in Table 2, and the 
process of data extraction for drugs is shown in Figure 2.
Relationship Between Drug Use and 
Survival Discharge
Logistic regression analysis indicated significant positive 
correlation between the administration of candidate drugs (the 
explanatory variable) and survival discharge within 1 year (the 
objective variable) for isosorbide dinitrate (OR = 3.80, 95% CI = 
2.52–5.66), nitroglycerin (OR = 2.79, 95% CI = 1.59–4.74), and 
nicardipine (OR = 2.27, 95% CI = 1.25-3.99) (Table 3).
Propensity score matching was performed to minimize patient 
background bias in the treatment and non-treatment groups. 
Standardized effects of each covariate before and after adjustment 
using the IPTW method are shown in Tables 4, 5, 6. The values 
of standardized effect decreased after adjustment compared with 
the values before adjustment, and the patient background bias was 
uniform. The adjusted odds ratios after adjustment with the IPTW 
method were as follows: isosorbide dinitrate, 3.35 (95% CI = 1.79–
6.26); nitroglycerin, 5.44 (95% CI  = 3.06–9.68); and nicardipine, 
4.58 (95% CI = 2.53–8. 28) (Table 7). These findings suggest 
that the survival discharge rate was significantly high in all three 
treatment groups.
DISCUSSION
Even after matching on covariates using propensity scores, the odds 
ratios for survival discharge within 1 year after cardiac arrest were 
significantly high in each of the isosorbide dinitrate, nitroglycerin, 
and nicardipine administration groups. This indicated that all three 
drugs improved the survival rate on hospital discharge.
To date, no large-scale clinical studies demonstrating the 
efficacy of nitroglycerin, isosorbide dinitrate, and nicardipine in 
cardiac arrest patients have been reported. However, some case 
reports were published reporting resuscitation being achieved by 
the administration of nitroglycerin in refractory cardiac arrest 
(Ward and Reid, 1984; Osada et al., 2000; Stefaniotou et al., 2014). 
Moreover, it was reported that acute coronary syndrome (ACS), 
which occurs after resuscitation from cardiac arrest, and cardiac 
arrest caused by ACS were improved by the administration of 
isosorbide dinitrate (Heming et al., 2010; Manzo-Silberman et al., 
2010). In animal experiments using the heart of a paralyzed rat, 
nicardipine administration significantly improved blood flow in 
ischemic state (Tachibana, 1990; Mitchell et al., 1992).
Nitrate drugs, such as nitroglycerin and isosorbide dinitrate, 
stimulate guanylate cyclase in vascular smooth muscle cells via 
nitrogen oxide. At low doses, nitrates dilate the vessels in the venous 
system and at high doses dilate the arterial system vessels to reduce 
resistance. They provide stress relief (by pulmonary capillary 
pressure reduction) and afterload relief (by mild elevation of cardiac 
output and decrease in peripheral vascular resistance). Moreover, 
nitrates are widely used in heart failure caused by ischemic heart 
disease for their coronary artery dilation effect.
FIGURE 1 | Timeline of claims data analysis. The cardiac arrest date was set as day 0. The frequency of survival discharge within 1 year after cardiac arrest was 
determined. Only administration of candidate drugs limited to 1 month or less after cardiac arrest was included. The medical history and emergency treatment 
recorded before cardiac arrest and on the day of cardiac arrest were included, respectively.
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TABLE 1 | Names of shortlisted candidate drugs extracted using TargetMine (excluding duplicates).
Drug names (165)
Ajmaline Doxazosin Lidocaine hydrochloride Propafenone
Amiodarone Doxazosin mesylate Lidocaine hydrochloride monohydrate Propafenone hydrochloride
Amiodarone hydrochloride Dronedarone Lidoflazine Propyl nitrate
Amlodipine Dronedarone hydrochloride Lorajmine hydrochloride Quinidine
Amlodipine besylate Encainide Lorcainide Quinidine gluconate
Amlodipine maleate Encainide hydrochloride Lorcainide hydrochloride Quinidine phenylethyl barbiturate
Aprindine Ergoloid mesylates Manidipine Quinidine polygalacturonate
Aprindine hydrochloride Erythrityl tetranitrate Manidipine hydrochloride Quinidine sulfate
Azapetine Ethacizine Methyl nicotinate Sparteine
Bamethan Fasudil Mexiletine Sparteine sulfate
Bamethan sulfate Fasudil hydrochloride Mexiletine hydrochloride Suloctidil
Barnidipine Fasudil hydrochloride hydrate Mibefradil Tedisamil
Barnidipine hydrochloride Felodipine Mibefradil dihydrochloride Tedisamil sesquifumarate
Bencyclane Fendiline Moricizine Tocainide
Bencyclane fumarate Fendiline hydrochloride Moricizine hydrochloride Tocainide hydrochloride
Benidipine Flecainide Moxisylyte Tolazoline
Benidipine hydrochloride Flecainide acetate Moxisylyte hydrochloride Tolazoline hydrochloride
Benzyl nicotinate Gallopamil Nafronyl oxalate Trimazosin
Bepridil Gallopamil hydrochloride Naftidrofuryl Trimazosin hydrochloride
Bepridil hydrochloride Guanazodine Niacin Trolnitrate phosphate
Bethanidine sulfate Guanethidine Nicardipine Urapidil
Bretylium tosylate Guanethidine sulfate Nicardipine hydrochloride Urapidil hydrochloride
Buflomedil Guanoclor sulfate Nicergoline Verapamil
Buflomedil hydrochloride Guanoxabenz Nicergoline tartrate Verapamil hydrochloride
Bunaftine Guanoxan sulfate Nicotinyl alcohol Vernakalant hydrochloride
Buphenine Hydroquinidine Nifedipine Vinburnine
Butalamine Hydroquinidine hydrochloride Nilvadipine Vincamine
Cetiedil citrate Ibutilide Nimodipine Vincamine hydrochloride
Ciclonicate Ibutilide fumarate Nisoldipine Visnadine
Cifenline Ifenprodil Nitrendipine Xanthinol niacinate
Cifenline succinate Ifenprodil tartrate Nitroglycerin
Cilnidipine Indoramin Nylidrin hydrochloride
Cinepazide maleate Indoramin hydrochloride Pentaerythritol tetranitrate
Clevidipine Inositol niacinate Pentifylline
Cyclandelate Isosorbide dinitrate Pentoxifylline
Debrisoquin Isosorbide mononitrate Perhexiline
Debrisoquin sulfate Isoxsuprine Perhexiline maleate
Dihydroergocristine Isoxsuprine hydrochloride Phenoxybenzamine
Dihydroergocristine mesilate Isoxsuprine lactate Phenoxybenzamine hydrochloride
Diltiazem Isradipine Phentolamine
Diltiazem hydrochloride Kallidinogenase Phentolamine mesylate
Diltiazem maleate Lacidipine Prazosin
Disopyramide Lercanidipine Prazosin hydrochloride
Disopyramide phosphate Lercanidipine hydrochloride Procainamide
Dofetilide Lidocaine Procainamide hydrochloride
TABLE 2 | Number of cardiac arrest patients administered each drug.
Drug name Number of patients 
administered
Drug name Number of patients administered Drug name Number of patients 
administered
Ajimarin 0 Diltiazem 45 Fassille 5
Apringin 9 Cilnidipine 0 Felodipine 0
Amiodarone 119 Doxazosin 0 Phentolamine 0
Amlodipine 0 Trazoline 0 Prazosin 0
Isoxsuprine 0 Niacin 0 Flecainide 28
Inositol 0 Nicardipine 98 Procainamide 10
Ifenprodil 0 Nicergoline 0 Propafenone 0
Urapidil 0 Nisoldipine 0 Benidipine 0
Kallidinogenase 0 Nitrangepin 0 Bepridil 0
Quinidine 0 Nitroglycerin 103 Verapamil 134
Guanethidine 0 Nifedipine 0 Mexiletine 2
Disopyramide 32 Nilvadipine 0 Lidocaine 559
Dihydroergocristine 0 Barnidipine 0 Isosorbide nitrate 164
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FIGURE 2 | Selection flowchart of candidate drug. First, 165 approved 
drugs having vasodilator activity were extracted using the drug discovery 
tool TargetMine. Next, drugs that were not approved in Japan, oral drugs, 
and external drugs were excluded, and seven drugs were selected that were 
administered to ≥10 patients within 1 month of cardiac arrest.
Dihydropyridine (DHP) calcium antagonists, such as nicardipine, 
relax vascular smooth muscles by blocking the membrane voltage-
dependent L-type calcium channels involved in the influx of 
extracellular calcium ions. They are used to treat hypertension by 
relaxing muscles and reducing peripheral vascular resistance. Their 
main pharmacological actions include coronary and peripheral 
vasodilator activity, cardiac contractility, and suppression of 
impulse conduction system. However, cardiac suppression is hardly 
seen at clinical doses. Nicardipine has excellent organ blood flow 
maintenance effect and is used in cases of organ failure due to 
hypertension. Among DHP calcium antagonists, nicardipine has a 
short onset time and half-life. It is used for hypertensive emergencies 
and is highly specific for cerebral blood vessels (Takenaka and 
Handa, 1979).
One common pharmacological effect of the three selected 
agents (isosorbide dinitrate, nitroglycerine, and nicardipine) is 
dilation of the coronary artery, which we suggest contributed to 
the improvement in survival rate after cardiac arrest in this study. 
Treatment of patients with cardiac arrest involves management 
of blood pressure; vasoconstrictors such as adrenaline and 
TABLE 3 | Relationship between each drug and survival discharge.
Explanatory variable p value Odds ratio (95% CI)
Diltiazem 0.573 0.76 (0.27–1.87)
Disopyramide 0.199 1.92 (0.64–4.82)
Flecainide 0.272 1.79 (0.57–4.74)
Verapamil 0.181 1.45 (0.82–2.43)
Isosorbide nitrate  <0.001 3.80 (2.52–5.66)
Nicardipine 0.006 2.27 (1.25–3.99)
Nitroglycerin  <0.001 2.79 (1.59–4.74)
TABLE 4 | Comparison of isosorbide dinitrate covariates.






Before adjustment After adjustment
Male 83.5% (137) 71.8% (1482) 0.26 0.07
Age 56.1 [10.5] 55.0 [13.3] 0.09 0.08
Medical history
 Ischemic heart disease 26.8% (44) 18.7% (385) 0.21 0.01
 Cerebrovascular disease 9.1% (45) 12.2% (252) 0.09 0.02
 Kidney disease 6.7% (11) 8.8% (181) 0.07 0.08
 Liver disease 15.9% (26) 19.0% (392) 0.08 0.12
 Chronic lung disease 22.0% (36) 24.6% (507) 0.06 0.1
 Heart failure 19.5% (32) 24.5% (506) 0.12 0.11
 Diabetes mellitus 34.1% (56) 23.8% (491) 0.24 0.04
 High blood pressure 42.7% (70) 39.1% (806) 0.07 0.11
 Hyperlipidemia 28.7% (47) 20.2% (416) 0.21 0.1
 Malignant neoplasm 10.4% (17) 20.2% (417) 0.25 0.12
Emergency treatment factor
 Out-of-hospital cardiac arrest 25.6% (42) 18.1% (373) 0.19 0.13
 Average number of instances of 
defibrillation 
0.40 [0.49] 0.29 [0.49] 0.23 0.17
 Tracheal intubation 27.4% (45) 20.5% (422) 0.17 0.04
 Artificial respiration 32.9% (54) 27.5% (567) 0.12 0.06
 Hypothermia 9.1% (15) 1.0% (21) 0.64 0.03
 Average number of adrenaline doses 0.64 [1.78] 1.38 [3.55] 0.21 0.04
 Vasopressin 0.61% (1) 0.5% (11) 0.01 0.05
 Amiodarone 20.1% (33) 2.4% (49) 0.94 0.01
 Lidocaine 17.7% (29) 2.9% (60) 0.75 0.01
 Nifekalant 2.4% (4) 0.5% (10) 0.25 0.23
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TABLE 5 | Comparison of nitroglycerin covariates.






Before adjustment After adjustment
Male 79.6% (82) 72.4% (1537) 0.16 0.01
Age 56.4 [12.6] 55.0 [13.2] 0.11 0.08
Medical history
 Ischemic heart disease 30.1% (31) 18.7% (398) 0.29 0.12
 Cerebrovascular disease 14.6% (15) 11.9% (252) 0.08 0.09
 Kidney disease 12.6% (13) 8.4% (179) 0.15 0.05
 Liver disease 13.6% (14) 19.0% (404) 0.14 0.01
 Chronic lung disease 24.3% (25) 24.4% (518) 0 0
 Heart failure 24.3% (25) 24.2% (513) 0 0.06
 Diabetes mellitus 26.2% (27) 24.5% (520) 0.04 0.01
 High blood pressure 49.5% (51) 38.8% (825) 0.22 0.05
 Hyperlipidemia 22.3% (23) 20.7% (440) 0.04 0
 Malignant neoplasm 12.6% (13) 19.8% (421) 0.18 0.03
Emergency treatment factor
 Out-of-hospital cardiac arrest 23.3% (24) 18.4% (391) 0.13 0.05
 Average number of instances of 
defibrillation 
0.42 [0.85] 0.29 [0.46] 0.26 0.06
 Tracheal intubation 27.2% (28) 20.7% (439) 0.16 0.03
 Artificial respiration 41.7% (43) 27.2% (578) 0.32 0.04
 Hypothermia 7.8% (8) 1.3% (28) 0.51 0.03
 Average number of adrenaline 
doses
1.12 [2.88] 1.34 [3.48] 0.06 0.06
 Vasopressin 0.0% (0) 0.6% (12) 0.08 0.08
 Amiodarone 13.6% (14) 3.2% (68) 0.55 0.11
 Lidocaine 27.2% (28) 2.9% (61) 1.24 0.08
 Nifekalant 1.9% (2) 0.6% (12) 0.17 0.04
TABLE 6 | Comparison of nicardipine covariates.






Before adjustment After adjustment
Male 76.5% (75) 72.5% (1544) 0.09 0.05
Age 58.0 [10.9] 54.9 [13.2] 0.23 0
Medical history
 Ischemic heart disease 28.6% (28) 18.8% (401) 0.25 0.07
 Cerebrovascular disease 18.4% (18) 11.7% (249) 0.21 0.03
 Kidney disease 8.2% (8) 8.6% (184) 0.02 0.01
 Liver disease 17.3% (17) 18.8% (401) 0.04 0
 Chronic lung disease 24.5% (24) 24.4% (519) 0 0.05
 Heart failure 26.5% (26) 24.0% (512) 0.06 0.09
 Diabetes mellitus 28.6% (28) 24.4% (519) 0.1 0.15
 High blood pressure 53.1% (52) 38.7% (824) 0.29 0.05
 Hyperlipidemia 27.6% (27) 20.5% (436) 0.17 0.03
 Malignant neoplasm 18.4% (18) 19.5% (416) 0.03 0.1
Emergency treatment factor
 Out-of-hospital cardiac arrest 28.6% (28) 18.2% (387) 0.27 0.06
 Average number of instances of 
defibrillation 
0.32 [0.49] 0.28 [0.49] 0.04 0.03
 Tracheal intubation 35.7% (35) 20.3% (432) 0.38 0.04
 Artificial respiration 53.1% (52) 26.7% (569) 0.59 0.11
 Hypothermia 8.2% (8) 1.3% (28) 0.54 0.02
 Average number of adrenaline 
doses
1.78 [3.72] 1.31 [3.44] 0.14 0.01
 Vasopressin 0.0% (0) 0.6% (12) 0.08 0.08
 Amiodarone 9.2% (9) 3.4% (73) 0.31 0.03
 Lidocaine 27.6% (27) 2.9% (62) 1.26 0.01
 Nifekalant 3.1% (3) 0.5% (11) 0.32 0.05
Drug Repositioning for Cardiac ArrestZamami et al.
8 November 2019 | Volume 10 | Article 1257Frontiers in Pharmacology | www.frontiersin.org
noradrenaline are commonly administered for this purpose. 
However, no sufficient evidence is available to support the effect of 
vasoconstrictors on the survival and discharge rate of adult patients 
after resumption of heart rate; excessive administration may lead 
to decreased blood flow. The prognosis improvement could have 
resulted from increased oxygen supply to the heart through the 
dilation of the coronary artery, relief in the heart afterload, and the 
increase in whole organ blood flow to the heart.
In addition, nicardipine has been shown to directly dilate cerebral 
blood vessels (Takenaka and Handa, 1979) and nitroglycerin has 
been reported to improve neurologic prognosis after cardiac arrest 
in animal studies (Chen et al., 2011). Irreversible damage to cranial 
nerves in post-cardiac arrest syndrome (PCAS), reported in most 
patients with cardiac arrest, is a very important risk factor for 
long-term poor prognosis of cardiac arrest patients. Thus, it can 
be suggested that increased cerebral blood flow, which suppresses 
irreversible damage to the cranial nerves associated with circulatory 
failure, also contributed to the improvement of long-term outcomes.
This study has several limitations. First, we could not evaluate 
the effect of drugs not approved in Japan. Because the JMDC 
claims database contains only Japanese claim data, we could only 
include drugs approved in Japan in the analysis. Thus, we may have 
missed promising drug candidates, which should be considered in 
future studies. Second, we defined each comorbidity based on the 
description in the claim data. However, the diagnostic methods and 
diagnosis criteria could be inconsistent, and, thus, the quality of 
diagnosis might be inconsistent. Third, the JMDC claims database 
does not provide some information, such as the cause of cardiac 
arrest, the quality of cardiopulmonary resuscitation, medication 
adherence, the dose and duration of drug administration, and 
clinical laboratory test results. In the studies using propensity scores, 
all factors affecting treatment allocation should be investigated 
and included as covariates. However, propensity score matching 
cannot be used as a substitute to the randomized comparison trials, 
which can balance out unknown covariates. In future, prospective 
observational studies should be conducted and information on 
background factors related to cardiac arrest should be collected.
CONCLUSION
Three drugs (isosorbide dinitrate, nitroglycerine, and nicardipine) 
were identified in this study as candidate novel therapeutic agents 
to improve the prognosis of cardiac arrest patients. These results 
could prove to be valuable in therapeutic drug development for 
cardiac arrest patients because it is difficult to conduct clinical 
trials in these patients due to the urgency of their treatment. 
Moreover, the procedure used for the identification of candidate 
drugs in the present study is a very useful method that combines 
multifaceted evaluation using drug discovery tools and claims 
databases. To confirm the usefulness of the results and method 
used in this study and to use the three identified drugs for their 
therapeutic effect in cardiac arrest patients, it is necessary to 
validate these results in clinical settings.
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TABLE 7 | Covariate adjusted odds ratios.
Drug name Adjusted odds ratio (95% 
CI)
p value
Isosorbide nitrate 3.35 (1.79–6.26)  <0.001
Nitroglycerin 5.44 (3.06–9.68)  <0.001
Nicardipine 4.58 (2.53–8.28)  <0.001
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